Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 30;14(1):104.
doi: 10.1186/s13045-021-01113-2.

Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies

Walter Hanel  1 , Narendranath Epperla  2   3
Affiliations
Review

Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies

Walter Hanel et al. J Hematol Oncol. .

Abstract

Follicular Lymphoma (FL) is the most common subtype of indolent B cell non-Hodgkin lymphoma. The clinical course can be very heterogeneous with some patients being safely observed over many years without ever requiring treatment to other patients having more rapidly progressive disease requiring multiple lines of treatment for disease control. Front-line treatment of advanced FL has historically consisted of chemoimmunotherapy but has extended to immunomodulatory agents such as lenalidomide. In the relapsed setting, several exciting therapies that target the underlying biology and immune microenvironment have emerged, most notable among them include targeted therapies such as phosphoinositide-3 kinase and Enhancer of Zeste 2 Polycomb Repressive Complex 2 inhibitors and cellular therapies including chimeric antigen receptor T cells and bispecific T cell engagers. There are several combination therapies currently in clinical trials that appear promising. These therapies will likely reshape the treatment approach for patients with relapsed and refractory FL in the coming years. In this article, we provide a comprehensive review of the emerging and investigational therapies in FL and discuss how these agents will impact the therapeutic landscape in FL.

Keywords: BiTe; CART; EZH2; Follicular lymphoma; PI3Ki.

PubMed Disclaimer

Conflict of interest statement

WH and NE has no relevant COI pertaining to the manuscript.

Figures

Fig. 1
Fig. 1
Approved (black) and emerging (red) therapies for follicular lymphoma
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi: 10.1182/blood-2016-01-643569. - DOI - PMC - PubMed
    1. Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol. 2018;93(2):296–305. doi: 10.1002/ajh.24937. - DOI - PubMed
    1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780–2795. doi: 10.1200/JCO.1998.16.8.2780. - DOI - PubMed
    1. Schmitt C, Balogh B, Grundt A, Buchholtz C, Leo A, Benner A, et al. The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validity. Leuk Res. 2006;30(6):745–750. doi: 10.1016/j.leukres.2005.10.001. - DOI - PubMed
    1. Summers KE, Goff LK, Wilson AG, Gupta RK, Lister TA, Fitzgibbon J. Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol. 2001;19(2):420–424. doi: 10.1200/JCO.2001.19.2.420. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources